uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Univ Minnesota, Schulze Diabet Inst, Minneapolis, MN 55455 USA.;Univ Minnesota, Dept Surg, Box 242 UMHC, Minneapolis, MN 55455 USA..
Univ Iowa, Clin Trials Stat & Data Management Ctr, Iowa City, IA USA..
NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA..
NIDDK, NIH, Bethesda, MD 20892 USA..
Show others and affiliations
2016 (English)In: Diabetes Care, ISSN 0149-5992, E-ISSN 1935-5548, Vol. 39, no 7, 1230-1240 p.Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50-80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA(1c) <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA(1c) level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.

Place, publisher, year, edition, pages
2016. Vol. 39, no 7, 1230-1240 p.
National Category
Endocrinology and Diabetes
URN: urn:nbn:se:uu:diva-308269DOI: 10.2337/dc15-1988ISI: 000381416500032PubMedID: 27208344OAI: oai:DiVA.org:uu-308269DiVA: diva2:1049301
Available from: 2016-11-24 Created: 2016-11-24 Last updated: 2016-11-24Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Korsgren, Olle
By organisation
Clinical Immunology
In the same journal
Diabetes Care
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 63 hits
ReferencesLink to record
Permanent link

Direct link